Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:5/19/2010

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 at 2:00 p.m. ET at the Hilton hotel, New York City and at the Jefferies 2010 Global Life Sciences Conference on June 10, 2010 at 4:00 p.m. ET at the Grand Hyatt hotel, New York City.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
2. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
6. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
7. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
8. Idenix Pharmaceuticals Reports First Quarter Financial Results
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Biotheranostics today ... the role of the Breast Cancer Index (BCI) ... breast cancer are most at-risk for disease recurrence ... include results from three studies advancing the understanding ... related to tumor biology and inform decisions related ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a leading ... interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's first FPGA-on-Module ... small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for low-cost ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 click” ... program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ and ...
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
Breaking Biology Technology:
(Date:12/7/2016)... to a new market research report "Emotion Detection and Recognition Market by Technology ... End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, the ... USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
Breaking Biology News(10 mins):